Targeted Treatment of Brain Metastases

  • Nicole Shonka
  • Vyshak Alva Venur
  • Manmeet S. Ahluwalia
Neuro-oncology (L Abrey, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuro-Oncology


Purpose of Review

Brain metastases are the most common intracranial tumors in adults. Historically, the median survival after the diagnosis of brain metastases has been dismal and medical therapies had a limited role in the management of these patients.

Recent Findings

The advent of targeted therapy has ushered in an era of increased hope for patients with brain metastases. The most common malignancies that result in brain metastases—melanoma, lung cancer, and breast cancer, often have actionable mutations, which make them good candidates for targeted systemic therapy. These brain metastases have been shown to have relevant and sometimes divergent genetic alterations, and there has been a resurgence of interest in targeted drug delivery to the brain by using standard or pulsatile dosing to achieve adequate concentration in the brain.


An increased understanding of oncogenic alterations, a surge in targeted drug development with good blood barrier penetration, and inclusion of patients with active brain metastases on clinical trials have led to improved outcomes for patients with brain metastases.


Targeted therapy Brain metastases Clinical trials EGFR ALK HER2 

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Nicole Shonka
    • 1
  • Vyshak Alva Venur
    • 2
  • Manmeet S. Ahluwalia
    • 3
  1. 1.Fred and Pamela Buffett Cancer CenterUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.University of Iowa Hospitals and ClinicsIowaUSA
  3. 3.Brain Metastasis Research Program, Burkhardt Brain Tumor and Neuro-Oncology Center, Department of Medicine, Cleveland ClinicNeurological InstituteClevelandUSA

Personalised recommendations